Skip to main content
NewslettersWatchlist

Rakovina Therapeutics Inc(RKV-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.085
Day High0.090
Open:0.090
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Select a category then submit the form to load news
Automated Summaries - The Globe and Mail
Closing Bell: Rakovina Therapeutics Inc flat on Tuesday (RKV)
GlobeNewswire
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
GlobeNewswire
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today
Baystreet
Stocks in play: Rakovina Therapeutics Inc.
GlobeNewswire
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
GlobeNewswire
Rakovina Therapeutics Announces Strategic Pivot to AI
AI-generated - The Globe and Mail
Rakovina Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (RKV)
GlobeNewswire
Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update
GlobeNewswire
Rakovina Therapeutics Welcomes Prof. Artem Cherkasov to the Company’s Scientific Advisory Board
GlobeNewswire
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
AI-generated - The Globe and Mail
Rakovina Therapeutics: Top 10 Undervalued Biotechnology Industry Stocks (RKV)
GlobeNewswire
Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update
GlobeNewswire
Rakovina Therapeutics Announces Results from 2023 Annual General Meeting
Globe Newswire
Rakovina Therapeutics Announces Results from Annual General Meeting
Globe Newswire
Rakovina Therapeutics Inc. Announces Q1 2022 Financial Results and Provides Corporate Update
Globe Newswire
Rakovina Therapeutics Inc. Announces 2021 Financial Results and Provides Corporate Update
Globe Newswire
InvestmentPitch Media Video Discusses Rakovina Therapeutics and its Presentation of Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research Annual General Meeting
Globe Newswire
Rakovina Therapeutics Presents Preclinical Data Supporting Potential Broad Anticancer Activity of kt-4000 Series at the American Association of Cancer Research (AACR) Annual General Meeting
Globe Newswire
Rakovina Therapeutics to Present Abstract at the 2022 AACR Special Conference – Sarcomas
Globe Newswire
Rakovina Therapeutics to Present Abstract at the 2022 Annual Meeting of the American Association of Cancer Research (AACR)
Globe Newswire
Rakovina Therapeutics Inc. to Present at Biotech Showcase 2022
Globe Newswire
Rakovina Therapeutics Announces Non-dilutive Financial Contributions to Support Lead Optimization of Novel Anti-cancer Agents
Globe Newswire
Rakovina Therapeutics Inc. Announces Third Quarter 2021 Financial Results and Provides Corporate Update
AccessWire
The Power Play by The Market Herald Releases New Interviews with Nextech AR, i-80 Gold, Kidoz Inc., Rakovina Therapeutics, Prophecy DeFi, and Saturn Oil & Gas Discussing Their Latest Press Releases
Globe Newswire
Rakovina Therapeutics Presents at the 6th biennial Canadian Cancer Research Conference
Globe Newswire
Rakovina Therapeutics to Present at the 6th biennial Canadian Cancer Research Conference
Globe NewsWire
CEO Presenting on the First Emerging Growth / Investors Hub Joint Conference on June 23. Register Now

Profile

Rakovina Therapeutics Inc is engaged in drug discovery research, preclinical and clinical development, and regulatory affairs necessary to advance breakthrough innovations to become potential life-changing treatments in the oncology field. Its oncology pipeline has the potential to deliver biomarker-driven treatments for patients across multiple tumor types. Some f its products in the pipeline include kt-2000 Next Generation PARP-inhibitors, kt-3000 Dual Action DDR-inhibitors, and kt-4000 DNA Damaging DDR-inhibitors.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.